Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Operating Expenses | 6,506 | 5,796 | 5,454 | 5,234 | 8,389 |
| Operating Income | -6,506 | -5,796 | -5,454 | -5,234 | -8,389 |
| Interest Expense | 2 | 2 | 2 | 17 | 22 |
| Other Income | 260 | 197 | 170 | 32 | 38 |
| Pre-tax Income | -6,248 | -5,601 | -5,286 | -5,219 | -8,373 |
| Net Income Continuous | -6,248 | -5,601 | -5,286 | -5,219 | -8,373 |
| Net Income Discontinuous | 169 | 70 | 47 | 370 | -302 |
| Net Income | $-6,079 | $-5,531 | $-5,239 | $-4,849 | $-8,675 |
| EPS Basic Total Ops | -0.12 | -0.10 | -0.11 | -0.09 | -0.17 |
| EPS Basic Continuous Ops | -0.12 | -0.11 | -0.10 | -0.10 | -0.16 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | 0.00 | 0.01 | -0.01 |
| EPS Diluted Total Ops | -0.12 | -0.10 | -0.11 | -0.09 | -0.17 |
| EPS Diluted Continuous Ops | -0.12 | -0.11 | -0.10 | -0.10 | -0.16 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | 0.00 | 0.01 | -0.01 |
| EBITDA(a) | $-6,246 | $-5,599 | $-5,284 | $-5,159 | $-8,294 |